http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
재조합 mannose-binding lectin 단백질과 anti-mannose-binding lectin polyclonal 항체 제작
권현미(Hyun Mi Kwon),박정애(Jung Ae Park),최병태(Byung Tae Choi),최영현(Yung Hyun Choi),정경태(Kyung Tae Chung) 한국생명과학회 2009 생명과학회지 Vol.19 No.2
선천성 면역은 숙주의 물리적 방어벽을 뚫고 침입하는 감염성 질병 원인균에 대항하는 첫 번째 방어로서 아주 중요한 역할을 한다. Mannose-binding lectin (MBL 또는 mannan-binding protein, MBP)은 혈청 내에 존재하는 면역성 단백질로서 감염 후 즉시 유발되는 acute phase response의 특정 단백질이다. MBL 단백질은 세균, 바이러스, 곰팡이, 기생충등의 탄수화합물 구조에 결합하여 식균 작용을 돕거나 보체경로를 활성화 시킨다. MBL 단백질은 C-말단이 탄수화물을 인식하는 도메인이며, 연결 목 부위와 콜라겐 부위로 구성되어 있다. 혈청 내의 MBL 농도가 낮으면 높은 빈도로 면역결핍현상이 관찰된다고 알려져 있다. MBL 단백질의 기능과 유전에 대해 많은 연구가 되어져 왔으나 아직 MBL 단백질 복합체등에 대한 연구는 많이 이루어져 있지 않다. 따라서 MBL 연구에 필수적인 MBL cDNA 제조와 재조합 단백질의 합성, 그리고 재조합 단백질을 항원으로 사용하여 polyclonal antibody를 생산한 연구 결과를 보고하는 바이다. 본 연구결과로 획득한 MBL cDNA, 재조합 단백질과 anti-MBL 항체는 앞으로의 MBL 연구에 절대적으로 필요한 도구가 될 것으로 생각된다. The innate immune system is important for the first line of host defence against infectious agents, which have penetrated the mechanical barriers. Mannose-binding lectin (MBL or mannan-binding protein, MBP) is a serum protein that is synthesized in the liver as a part of the acute phase response. MBL binds to carbohydrate structures presented by a wide range of pathogenic bacteria, viruses, fungi, and parasites. MBL is synthesized as a monomer that has a carboxy-terminal carbohydrate recognition domain, a neck region and a collagen region. Low MBL level was reported to be the most frequent immuno-deficiency syndrome. Although extensive studies have yielded detailed information on the structure of MBL, functions of the MBL complex are not fully understood yet. We, here, present cloning process of MBL cDNA from the rat liver and production of truncated recombinant MBL protein using a bacterial expression system in order to produce anti-MBL polyclonal antibody. Anti-MBL polyclonal antibody was raised in a New Zealand rabbit and its affinity was tested against recombinant protein using western blot technique. MBL cDNA, recombinant protein and anti-MBL antibody could be used as great arsenals to dissect cellular biochemistry of MBL.
증례 : 류마티스; 피부근염에 동반된 혈전혈소판감소자색반병에서 리툭시맙 치료 1예
권현미 ( Hyun Mi Kwon ),조현정 ( Hyun Jeong Cho ),양지애 ( Ji Ae Yang ),이상진 ( Sang Jin Lee ),김동기 ( Dong Ki Kim ),김인호 ( In Ho Kim ),이은영 ( Eun Young Lee ) 대한내과학회 2013 대한내과학회지 Vol.85 No.6
저자들은 피부근염에 동반된 혈전혈소판감소자색반병을 진단하고 고농도의 스테로이드 투약과 혈장교환술로 치료하였으나 일시적인 호전 이후 재발하여 면역억제제인 rituximab을 투약하였고 피부근염과 혈전혈소판감소자색반병이 호전된증례를 경험하였기에 문헌고찰과 함께 보고하는 바이다.
증례 : 류마티스 ; 만성 염증성 탈수초성 다발신경병증과 헤노흐-쇤라인 자반증을 동반한 강직성 척추염 1예
최병용 ( Byoong Yong Choi ),권현미 ( Hyun Mi Kwon ),성정준 ( Jung Jun Sung ),박성혜 ( Seong He Park ),송영욱 ( Yeong Wook Song ) 대한내과학회 2012 대한내과학회지 Vol.83 No.4
Peripheral nervous system dysfunction is a rare complication in Henoch-Schonlein purpura, but it tends to recover spontaneously without treatment. A 78-year-old man who had ankylosing spondylitis presented with Henoch-Schonlein purpura associated with progressive sensorimotor polyneuropathy. He was diagnosed with chronic inflammatory demyelinating polyneuropathy, which did not improve despite intravenous immunoglobulin therapy. We describe a case of Henoch-Schonlein purpura, accompanied by chronic inflammatory demyelinating polyneuropathy in a patient with ankylosing spondylitis. (Korean J Med 2012;83:538-542)
불응성 염증성 근병증 환자에 대한 Rituximab 치료
양지애 ( Ji Ae Yang ),이상진 ( Sang Jin Lee ),박준원 ( Jun Won Park ),권현미 ( Hyun Mi Kwon ),문진영 ( Jin Young Moon ),고동진 ( Dong Jin Ko ),장성혜 ( Sung Hae Chang ),박진균 ( Jin Kyun Park ),이은봉 ( Eun Bong Lee ),송영욱 ( Yeo 대한류마티스학회 2013 대한류마티스학회지 Vol.20 No.5
Objective. To assess the efficacy and safety of rituximab (RTX) on disease activity and muscle strength in patients with inflammatory myopathies refractory to conventional therapy. Methods. Four inflammatory myopathy patients who had been refractory to glucocorticoids, one or more immunosuppressive therapies and intravenous immunoglobulin were treated on an open-label basis. Each patient received two 500 mg doses of RTX 2 weeks apart in one cycle. In one patient who did not respond after the first cycle of RTX, the infusion schedule was modified by the physician. We measured muscle enzyme including CPK, LDH and assessed muscle strength individually to evaluate RTX response. Additionally anti-CD19 antibody was measured. Results. Three patients responded to the first cycle of RTX treatment with improvements in muscle enzyme and muscle strength, and then maintained physical function over the duration of several infusion cycles. In one patient, muscle enzyme did not decrease after the first cycle of RTX, and a high dose glucocorticoid was given. After modifying the treatment schedule with monthly RTX infusion, his muscle enzyme level and muscle strength improved. Anti-CD19 antibody decreased after RTX generally, but responses were variable. Herpes zoster infection occurred in two patients. Conclusion. Rituximab may be a therapeutic choice in refractory inflammatory myopathy. However a further trial is needed to confirm the efficacy and prove the safety.
이상진 ( Sang Jin Lee ),양지애 ( Ji Ae Yang ),박준원 ( Jun Won Park ),고동진 ( Dong Jin Ko ),권현미 ( Hyun Mi Kwon ),문진영 ( Jin Young Moon ),김영기 ( Young Ki Kim ),최영훈 ( Young Hoon Choi ),이은영 ( Eun Young Lee ) 대한류마티스학회 2014 대한류마티스학회지 Vol.21 No.3
저자들은 국내에서 처음으로 재발다발연골염에 생물학적 제제 사용으로 호전된 바 있는 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Relapsing polychondritis is an episodic, systemic inflammation of the cartilage with unknown autoimmune etiology. It leads to the destruction of cartilaginous structures of the ear, eye, nose, respiratory tract, joints, skin, and heart valve, and its presented symptoms are diverse. It can be improved mainly by corticosteroid or immunosuppressive agents. Recently, the use of biologic agents (TNF inhibitors, rituximab, tocilizumab et al) was reported from abroad. However, there is no reported case of relapsing polychondritis, which is treated by biologic agents in Korea. We report this first case of refractory relapsing polychondritis, which was improved with a treatment of Infliximab.